U.S. Markets open in 1 hr 55 mins
  • S&P Futures

    4,336.75
    -4.75 (-0.11%)
     
  • Dow Futures

    33,959.00
    -96.00 (-0.28%)
     
  • Nasdaq Futures

    14,174.25
    +15.75 (+0.11%)
     
  • Russell 2000 Futures

    1,966.50
    -6.20 (-0.31%)
     
  • Crude Oil

    88.09
    +0.74 (+0.85%)
     
  • Gold

    1,812.70
    -17.00 (-0.93%)
     
  • Silver

    23.20
    -0.61 (-2.55%)
     
  • EUR/USD

    1.1161
    -0.0084 (-0.7478%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    30.56
    -0.60 (-1.93%)
     
  • GBP/USD

    1.3393
    -0.0070 (-0.5183%)
     
  • USD/JPY

    115.2240
    +0.5640 (+0.4919%)
     
  • BTC-USD

    36,671.84
    -1,196.27 (-3.16%)
     
  • CMC Crypto 200

    837.38
    -18.43 (-2.15%)
     
  • FTSE 100

    7,510.88
    +41.10 (+0.55%)
     
  • Nikkei 225

    26,170.30
    -841.00 (-3.11%)
     

Investors Met With Slowing Returns on Capital At IntriCon (NASDAQ:IIN)

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • IIN

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Although, when we looked at IntriCon (NASDAQ:IIN), it didn't seem to tick all of these boxes.

Understanding Return On Capital Employed (ROCE)

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for IntriCon, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.029 = US$3.0m ÷ (US$123m - US$22m) (Based on the trailing twelve months to September 2021).

So, IntriCon has an ROCE of 2.9%. Ultimately, that's a low return and it under-performs the Medical Equipment industry average of 8.4%.

Check out our latest analysis for IntriCon

roce
roce

In the above chart we have measured IntriCon's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free report for IntriCon.

What Can We Tell From IntriCon's ROCE Trend?

There are better returns on capital out there than what we're seeing at IntriCon. Over the past five years, ROCE has remained relatively flat at around 2.9% and the business has deployed 258% more capital into its operations. Given the company has increased the amount of capital employed, it appears the investments that have been made simply don't provide a high return on capital.

On a side note, IntriCon has done well to reduce current liabilities to 17% of total assets over the last five years. Effectively suppliers now fund less of the business, which can lower some elements of risk.

In Conclusion...

Long story short, while IntriCon has been reinvesting its capital, the returns that it's generating haven't increased. Yet to long term shareholders the stock has gifted them an incredible 184% return in the last five years, so the market appears to be rosy about its future. Ultimately, if the underlying trends persist, we wouldn't hold our breath on it being a multi-bagger going forward.

Like most companies, IntriCon does come with some risks, and we've found 3 warning signs that you should be aware of.

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.